Findings

What do systematic reviews say?

12 questions · 18 findings · 2 reviews · Headline outcomes only

No studies found 5 · 27.8%GRADE not reported 0 · 0%Very low 3 · 16.7%Low 8 · 44.4%Moderate 2 · 11.1%High 0 · 0%

PEG interferon alpha‐2a · patients on HD with HCV infection

High showed no clear difference in PEG interferon alpha‐2a compared with low dose pegylated interferon alpha‐2a or alpha‐2b (low certainty).

4 findings from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 5.66 [0.69, 46.31]
1 study · 81 participants
Low
Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.12 [0.4, 2.21]
1 study · 43 participants
Low
Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.19 [0.79, 1.78]
1 study · 81 participants
Low

Show 1 more finding

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.13 [0.64, 2]
1 study · 81 participants
Low

PEG interferon (alpha‐2b) · patients on HD with HCV infection

High showed no clear difference in PEG interferon alpha‐2b compared with low dose pegylated interferon alpha‐2a or alpha‐2b (low certainty).

2 findings from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 2.4 [0.11, 51.32]
1 study · 16 participants
Low
Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 5.6 [0.34, 93.35]
1 study · 16 participants
Low

PEG interferon (combined) · patients on HD with HCV infection

High showed no clear difference in PEG interferon (combined) compared with low dose pegylated interferon alpha‐2a or alpha‐2b (moderate certainty).

3 findings from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 4.3 [0.76, 24.33]
2 studies · 97 participants
Moderate
Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.12 [0.4, 2.21]
1 study · 43 participants
Low
Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.05 [0.61, 1.83]
2 studies · 97 participants
Moderate

Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation

1 finding from 1 review

Osmotic and stimulant laxatives for the management of childhood constipation 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low

Need for extra treatment · patients aged 0 to 18 years with a diagnosis of functional constipation

It is very uncertain whether high dose PEG changes need for additional therapy compared with low dose PEG (very low certainty).

1 finding from 1 review

Osmotic and stimulant laxatives for the management of childhood constipation 2016 · Cochrane Headline outcomes only
RR 0 [0.24, 1.02]
1 study · 90 participants
Very low

Faecal incontinence · patients aged 0 to 18 years with a diagnosis of functional constipation

It is very uncertain whether high dose PEG changes faecal incontinence compared with low dose PEG (very low certainty).

1 finding from 1 review

Osmotic and stimulant laxatives for the management of childhood constipation 2016 · Cochrane Headline outcomes only
RR 0.17 [0.02, 1.39]
1 study · 90 participants
Very low

Adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation

It is very uncertain whether high dose PEG changes adverse events compared with low dose PEG (very low certainty).

1 finding from 1 review

Osmotic and stimulant laxatives for the management of childhood constipation 2016 · Cochrane Headline outcomes only
RR 1 [0.33, 5.88]
1 study · 90 participants
Very low